Tetracycline News and Research

RSS

Tetracycline is an antibiotic drug used to treat infection.

Low doses of antibiotics may serve as active mutagens and lead to multidrug resistance

Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry. To combat such bacteria, it is critical to understand how resistance is developed in the first place. It is commonly thought that an incomplete course of antibiotics would lead to resistance to that particular antibiotic by allowing the bacteria to make adaptive changes under less stringent conditions.

12 Feb 2010

Oral hygiene: Insights

Oral health is often the window to your overall health. Evidence has supported the link between poor oral health and such conditions as stroke, premature birth and diabetes. Other conditions, such as HIV/AIDS and osteoporosis may show preliminary signs in your mouth, before other areas of the body are affected. Also, some of your daily activities or habits can affect your oral health. Therefore, it's wise to pay attention to your teeth and gums.

11 Feb 2010

Researchers show how gliomas can evade drugs aimed at blocking EGFR

Researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine and Moores UCSD Cancer Center have shown one way in which gliomas, a deadly type of brain tumor, can evade drugs aimed at blocking a key cell signaling protein, epidermal growth factor receptor (EGFR),that is crucial for tumor growth.

20 Jan 2010

Some combination drug therapies are counter-productive

Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow.

16 Nov 2009

Tetracycline-like compound raises hope for treatment of spinal muscular atrophy

A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants. This is the finding of a research collaboration involving Adrian Krainer, Ph.D., of Cold Spring Harbor Laboratory (CSHL) and scientists from Paratek Pharmaceuticals and Rosalind Franklin University of Medicine and Science.

5 Nov 2009

Lovastatin-synthesizing enzyme successfully reconstituted

Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.

4 Nov 2009

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS).

19 Oct 2009

Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development

Paratek Pharmaceuticals, Inc. announced today that it has entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement with Novartis for Paratek's lead broad-spectrum antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC) in Phase 3 clinical trials.

8 Oct 2009

Non-human primate study results of Restanza released

Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.

30 Sep 2009

Neogen announces first-quarter results of fiscal 2010

Neogen Corporation announced today that its revenues for the first quarter of FY 2010, which ended Aug. 31, increased 12% from the previous year's first quarter to $32,347,000. First quarter net income increased 18% from the prior year's $3,733,000 to $4,395,000, or to $0.29 per share in the current year compared to the previous year's $0.25.

25 Sep 2009

Tetraphase to present its study on novel classes of antibiotics to treat drug-resistant infections

Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

11 Sep 2009

Giant Eagle offers generic prescription antibiotics for free at its in-store pharmacies

At a time when many families affected by a difficult economy are struggling with the costs of prescription medications, supermarket retailer Giant Eagle, Inc. is making ten broadly used generic prescription antibiotics in 46 common dosages available for free every day at all of its 210 in-store pharmacies.

4 Sep 2009

Research study discovers lethal effects of tetracycline and chloramphenicol against certain bacterial strains

By studying the intricate mechanisms at work in protein production, a Princeton-led team has discovered why certain kinds of antibiotics are so effective. In doing so, they also have discovered how one protein protects against cell death, shedding light on a natural cancer-fighting process.

21 Aug 2009

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH grant for the development of a high-throughput screening platform for anti-microbial drug discovery.

From Fluxion Biosciences 20 Aug 2009

Bloomberg examines China plague cases, potential for disease spread

"Plague-spreading fleas are expanding their territory, putting more people at risk of catching the lethal illness, a WHO official said," Bloomberg reports, in an article that examines the recent deaths of three people in China from the pneumonic plague.

6 Aug 2009

Dangerous liaisons: bacterial 'sex' causes antibiotic resistance

Some disease-causing bacteria are becoming resistant to antibiotics because they have peculiar sex lives, say researchers publishing new results today in the journal Science.

12 Jun 2009

Why does aspirin increase the susceptibility of Helicobacter pylori to antimicrobials?

Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori.

2 Apr 2009

Warner Chilcott files new lawsuit for infringement of DORYX patent

Warner Chilcott Limited has announced hat one of its subsidiaries and Mayne Pharma International Pty. Ltd. ("Mayne") have filed a second lawsuit against Impax Laboratories, Inc. ("Impax") in the District Court for the District of New Jersey for infringement of Mayne's U.S. Patent No. 6,958,161 (the "'161 Patent") which covers DORYX, a tetracycline-class oral antibiotic.

20 Mar 2009

Researchers create gene circuit that permits precise tuning of a gene's expression in a cell

Researchers have crafted a gene circuit that permits precise tuning of a gene's expression in a cell, an advance that should allow for more accurate analysis of the gene's role in normal and abnormal cellular function.

11 Mar 2009

Why does aspirin increase the susceptibility of Helicobacter pylori to antimicrobials?

Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori.

3 Mar 2009

Tetracycline News and Research

Low doses of antibiotics may serve as active mutagens and lead to multidrug resistance

Oral hygiene: Insights

Researchers show how gliomas can evade drugs aimed at blocking EGFR

Some combination drug therapies are counter-productive

Tetracycline-like compound raises hope for treatment of spinal muscular atrophy

Lovastatin-synthesizing enzyme successfully reconstituted

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development

Non-human primate study results of Restanza released

Neogen announces first-quarter results of fiscal 2010

Tetraphase to present its study on novel classes of antibiotics to treat drug-resistant infections

Giant Eagle offers generic prescription antibiotics for free at its in-store pharmacies

Research study discovers lethal effects of tetracycline and chloramphenicol against certain bacterial strains

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Bloomberg examines China plague cases, potential for disease spread

Dangerous liaisons: bacterial 'sex' causes antibiotic resistance

Why does aspirin increase the susceptibility of Helicobacter pylori to antimicrobials?

Warner Chilcott files new lawsuit for infringement of DORYX patent

Researchers create gene circuit that permits precise tuning of a gene's expression in a cell

Why does aspirin increase the susceptibility of Helicobacter pylori to antimicrobials?

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News